Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aclaris Therapeutics, Inc.
This open-label, single-arm study of ATI-2138 in moderate to severe AD participants between the ages of 18 and 60 years (inclusive) will investigate the safety, tolerability, pharmacokinetics, efficacy and pharmacodynamics of ATI-2138 administered over 12 weeks.
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Able to comprehend and willing to sign the IRB approved ICF/assent prior to administration of study-related procedures.
Male patients or non-pregnant, non-nursing female patients 18 to 60 years old, inclusive, at the time of informed consent/assent.
Have at least a 1-year history of moderate or severe AD prior to the Screening Visit, and no significant AD flares for the 4 weeks prior to the Screening Visit as determined by the Investigator upon review of participant medical history.
You may not be if
Any prior exposure to systemic (oral) JAK inhibitors or TYK inhibitors at any time prior to Screening.
Unstable course of AD (spontaneously improving or rapidly deteriorating) based on the patient history or as determined by the investigator during the Screening Period.
Refractory AD (ie, AD that required frequent hospitalizations and/or frequent intravenous treatment for skin infections within the year before the Screening Visit).
Concomitant skin disease or clinically infected AD or presence of other skin disease in the area to be dosed that may interfere with study assessments.
Female patients who are pregnant, nursing, or planning to become pregnant during the study.
Clareo Health | Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis
